@marioramirezfit's menopause claims need context

What did @marioramirezfit actually say?

The caption, not the transcript, is doing the real work here. The transcript is largely incoherent audio, a garbled mix of Spanish fragments and unrelated English text that appears to be auto-generated garbage. So we're fact-checking the caption, which claims: menopause begins when estrogen drops and the hypothalamus loses its regulatory signal, that "neuronas que coordinan el ciclo hormonal se desregulan," and that this collapse of the thermoneutral zone produces hot flashes. The final line insists "no es psicológico."

These are real mechanistic claims about menopause physiology. They deserve a real answer, even if the video's audio couldn't deliver one.

Does the science back this up?

Mostly, yes. The core claim about KNDy neurons is legitimate neuroscience. The mechanistic story here is well-supported, though oversimplified in places.

The hypothalamic thermoregulation model for vasomotor symptoms has solid backing. Research by Rance and colleagues (2007, Endocrinology) identified that KNDy neurons in the arcuate nucleus, which co-express kisspeptin, neurokinin B, and dynorphin, become hypertrophied and hyperactive after estrogen withdrawal. These neurons project directly to the median preoptic area, the brain's thermostat. Deecher and Dorries (2007, Endocrine Reviews) confirmed that loss of estrogen feedback causes KNDy neurons to fire erratically, bombarding heat-dissipation neurons and narrowing the thermoneutral zone. Freedman (2014, Menopause) put the thermoneutral zone narrowing in hot-flash sufferers at less than 0.4 degrees Celsius, versus nearly 2 degrees in asymptomatic women. That is a real physiological finding, not a metaphor.

The claim that this starts before the final menstrual period is also accurate. Follicular reserve declines for years before periods stop, and estrogen fluctuation during perimenopause, not just its absence, is when symptoms often peak.

What did they get wrong (or right)?

The framing is mostly right, but with two meaningful gaps. First, saying estrogen "falls" as the singular trigger is too clean. During perimenopause, estrogen is erratic, sometimes spiking above premenopausal levels before declining. It is the loss of rhythmic estrogen signaling, not simply low estrogen, that destabilizes KNDy neuron firing. Joffe and colleagues (2020, JAMA Internal Medicine) found vasomotor symptom frequency correlates more with estrogen variability than with absolute levels in the early menopausal transition.

Second, the hashtags include SS31, MOTSC, and GHK-Cu. None of these peptides have peer-reviewed human evidence for treating menopausal vasomotor symptoms. SS31 is a mitochondria-targeted antioxidant studied in cardiac and renal ischemia models. MOTSC is a mitochondrial peptide with early metabolic research in rodents. Connecting these to the menopause mechanism described in the caption is not supported by clinical data. The caption does not explicitly make that connection, but the hashtag pairing implies it, and that implication is unsubstantiated.

The "no es psicológico" line is fair pushback against historical dismissal of hot flashes as anxiety or hysteria. That dismissal was wrong. The neurobiology is real.

What should you actually know?

The KNDy neuron model has moved from animal research to clinical application. Fezolinetant, a neurokinin B receptor antagonist, received FDA approval in 2023 specifically because it targets this pathway. That is the strongest evidence that the mechanism described in this caption is correct enough to build drugs around.

What this video does not tell you is that the same pathway also affects sleep, mood, and cognition, symptoms that get mislabeled as psychological when they are neurochemical. Santoro and colleagues (2021, New England Journal of Medicine) reviewed evidence linking KNDy dysregulation to sleep fragmentation and cognitive fog in menopausal women.

If you are experiencing vasomotor symptoms, the biology is real and treatable. Hormone therapy remains the most effective intervention for most women without contraindications, per the Menopause Society 2023 position statement. Peptide therapies mentioned in the hashtags are not FDA-approved for menopause management and lack clinical trial data for this indication. Anyone considering compounded peptides should have that conversation with a licensed clinician, not an Instagram caption.